References
- TeramotoSYamamotoHYamaguchiYMatsuseTOuchiYGlobal burden of COPD in Japan and AsiaLancet200336293971764176514643136
- FukuchiYNishimuraMIchinoseMCOPD in Japan: the Nippon COPD Epidemiology studyRespirology20049445846515612956
- Global Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Updated 2016. Available from: http://goldcopd.org/Accessed January 29, 2016
- CelliBRMacNeeWATS/ERS Task ForceStandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J200423693294615219010
- YohannesAMWillgossTGVestboJTiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomesRespir Care201156447748721255503
- VogelmeierCHedererBGlaabTTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
- RodrigoGJNanniniLJTiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysisPulm Pharmacol Ther200720549550216621638
- BouyssouTCasarosaPNalineEPharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical modelsJ Pharmacol Exp Ther20103341536220371707
- BeehKMWestermanJKirstenAMThe 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary diseasePulm Pharmacol Ther201532535925956072
- SinghDFergusonGTBolitschekJTiotropium + olodaterol shows clinically meaningful improvements in quality of lifeRespir Med2015109101312131926320402
- BeehKMDeromEEchave-SustaetaJThe lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study)Int J Chron Obstruct Pulmon Dis20161119320526893551
- IchinoseMTakizawaAIzumotoTEfficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis2015101673168326316741
- BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
- JonesPWEstimation and application of the minimum clinically important difference in COPDLancet Respir Med201423167169
- HosoeMWoessnerRMatsushimaSLawrenceDKramerBEfficacy, safety and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease: a comparison of data from two randomized, placebo-controlled studiesClin Drug Investig2011314247255
- MuruganandanSJayaramLProfile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPDInt J Chron Obstruct Pulmon Dis2015101179118926124657
- MolimardMColthorpePInhaler devices for chronic obstructive pulmonary disease: insights from patients and healthcare practitionersJ Aerosol Med Pulm Drug Deliv201528321922825265316